Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19004480 | IMMUNOMODULATORY HYDROGEL AND PREPARATION METHOD THEREOF | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18889070 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | September 2024 | January 2025 | Allow | 4 | 0 | 0 | No | No |
| 18889023 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | September 2024 | December 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18889055 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | September 2024 | February 2025 | Allow | 5 | 0 | 0 | No | No |
| 18760757 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | July 2024 | June 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18758699 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | June 2024 | December 2024 | Allow | 6 | 1 | 0 | No | No |
| 18759320 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | June 2024 | February 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18759364 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | June 2024 | December 2024 | Allow | 6 | 1 | 0 | No | No |
| 18758081 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | June 2024 | October 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18643773 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18441901 | METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUG | February 2024 | August 2025 | Allow | 18 | 1 | 0 | No | No |
| 18539960 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18539946 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18537332 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18537318 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18537342 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | June 2024 | Allow | 6 | 1 | 0 | No | No |
| 18531095 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18531056 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | June 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18520348 | PREPARATION OF SOLID DOSAGE FORMS COMPRISING ANTIBODIES BY SOLUTIONS/SUSPENSION LAYERING | November 2023 | February 2026 | Allow | 27 | 2 | 0 | No | No |
| 18562898 | AN ADVENTITIAL PAINTING MODALITY OF LOCAL DRUG DELIVERY TO ABATE INTIMAL HYPERPLASIA | November 2023 | March 2026 | Allow | 28 | 1 | 1 | No | No |
| 18388699 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | November 2023 | July 2024 | Allow | 8 | 2 | 0 | No | No |
| 18472901 | MOLECULAR ENTRAPMENT VIA HOMOPOLYMER SELF-ASSEMBLY | September 2023 | July 2025 | Allow | 22 | 1 | 0 | No | No |
| 18368403 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | September 2023 | July 2024 | Allow | 10 | 2 | 0 | No | No |
| 18241799 | MODULAR TRANSDERMAL DELIVERY SYSTEM AND ASSOCIATED METHODS OF MANUFACTURE AND USE | September 2023 | March 2026 | Abandon | 30 | 1 | 1 | No | No |
| 18231581 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | August 2023 | November 2023 | Allow | 3 | 1 | 0 | Yes | No |
| 18212233 | ISOXAZOLINE COMPLEXES AND COMPOSITIONS THEREOF | June 2023 | December 2023 | Allow | 6 | 2 | 0 | Yes | No |
| 18144220 | NOVEL ISOXAZOLINE COMPLEXES AND COMPOSITIONS THEREOF | May 2023 | November 2023 | Abandon | 7 | 1 | 0 | No | No |
| 18141610 | Solid Oral Sulfate Salt Formulations For Cleaning A Colon And Methods of Using Same | May 2023 | February 2026 | Allow | 34 | 2 | 0 | No | No |
| 18134050 | COMPOSITION FOR IMPROVING EYESIGHT | April 2023 | November 2025 | Allow | 32 | 1 | 0 | No | No |
| 18120231 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | March 2023 | April 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18119477 | EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE | March 2023 | June 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18179283 | EMOLLIENT TOPICAL DISINFECTANTS | March 2023 | April 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18022372 | COMPOSITIONS OF GINSENOSIDE RG3 AND GINSENOSIDE RG5 AND THEIR PHARMACEUTICAL USES INCLUDING ANTI-TUMOR EFFECTS | February 2023 | December 2025 | Abandon | 34 | 0 | 1 | No | No |
| 18018473 | A COMPOSITION COMPRISING AN EXTRACT OF ALDER TREE OR THE ISOLATED COMPOUNDS THEREFROM FOR TREATING AND PREVENTING SKELETON MUSCLE-RELATED DISORDER AND THE USE THEREOF | January 2023 | December 2025 | Abandon | 35 | 0 | 1 | No | No |
| 18005853 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | January 2023 | March 2026 | Allow | 38 | 1 | 0 | No | No |
| 18096508 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | January 2023 | August 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18150741 | TABLETS HAVING DISCONTINUOUS COATED REGIONS | January 2023 | November 2025 | Allow | 35 | 1 | 0 | No | No |
| 18013919 | DRUG-CLAY MINERAL COMPLEX CONTAINING PHOSPHOLIPID AND ORAL ADMINISTRATION COMPOSITION INCLUDING SAME | December 2022 | January 2026 | Allow | 36 | 1 | 1 | No | No |
| 18083477 | Liver Vitality | December 2022 | March 2026 | Abandon | 39 | 1 | 1 | No | No |
| 18063281 | SAUVIGNON BLANC GRAPE SEED PRODUCTS FOR NONALCOHOLIC FATTY LIVER DISEASE | December 2022 | March 2026 | Abandon | 39 | 1 | 0 | No | No |
| 18075980 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2022 | July 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18061848 | METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUG | December 2022 | January 2024 | Allow | 13 | 1 | 0 | No | No |
| 18053557 | Rucaparib particles and uses thereof | November 2022 | March 2023 | Allow | 4 | 0 | 1 | No | No |
| 17922884 | COMPOSITION TO BE USED FOR STRENGTHENING THE IMMUNE SYSTEM IN HUMAN AND ANIMAL TO ACQUIRE PAN-IMMUNITY | November 2022 | November 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17966538 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | October 2022 | September 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 18045075 | ANTI-VIRAL CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF | October 2022 | June 2025 | Allow | 32 | 2 | 1 | No | No |
| 17959746 | BIOERODIBLE DRUG DELIVERY DEVICES | October 2022 | September 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17912625 | TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES MELLITUS 10 TYPE I AND TYPE II AND THYROID DISEASES | September 2022 | February 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17946243 | EXTENDED RELEASE, ABUSE DETERRENT DOSAGE FORMS | September 2022 | September 2024 | Allow | 24 | 1 | 0 | No | No |
| 17908079 | USE OF COMPOUNDS IN THE TREATMENT OF FUNGAL INFECTIONS | August 2022 | November 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17821786 | Bis-Choline Tetrathiomolybdate for Treating Wilson Disease | August 2022 | October 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17883902 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | August 2022 | August 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17851451 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | June 2022 | March 2025 | Allow | 32 | 0 | 1 | Yes | No |
| 17851590 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | June 2022 | March 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17849328 | OPHTHALMIC COMPOSITIONS AND METHODS FOR REDUCING OXIDATIVE DAMAGE TO AN EYE LENS | June 2022 | May 2025 | Allow | 35 | 1 | 1 | Yes | No |
| 17839940 | PATHOGEN DESTRUCTION SYSTEM AND METHOD USING MAGNETIC MARKERS | June 2022 | March 2026 | Allow | 45 | 2 | 0 | Yes | Yes |
| 17838636 | METHOD OF TREATING PAIN UTILIZING CONTROLLED RELEASE OXYMORPHONE PHARMACEUTICAL COMPOSITIONS AND INSTRUCTION ON DOSING FOR RENAL IMPAIRMENT | June 2022 | March 2026 | Abandon | 45 | 2 | 0 | No | Yes |
| 17834839 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA, A DOPAMINE DECARBOXYLASE INHIBITOR AND A COMT INHIBITOR AND METHOD OF ADMINISTRATION THEREOF | June 2022 | August 2024 | Allow | 26 | 1 | 0 | No | No |
| 17804312 | CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF | May 2022 | September 2024 | Allow | 28 | 1 | 0 | No | No |
| 17775889 | INFANT FORMULA WITH SPECIAL LIPID ARCHITECTURE FOR IMPROVING POSTNATAL GROWTH OF INFANTS BORN BY CAESAREAN SECTION | May 2022 | March 2023 | Allow | 10 | 1 | 0 | No | No |
| 17729162 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | April 2022 | December 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17722158 | IMMEDIATE-RELEASE TABLETS CONTAINING A DRUG AND PROCESSES FOR FORMING THE TABLETS | April 2022 | August 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17697084 | BIOERODIBLE DRUG DELIVERY DEVICES | March 2022 | February 2025 | Allow | 35 | 2 | 0 | No | No |
| 17691552 | Compositions and Methods for Attracting Mosquitoes and Repelling Sand Flies | March 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17689255 | MODIFIED RELEASE COMPOSITIONS OF NAFAMOSTAT AND METHODS OF USING SAME | March 2022 | November 2025 | Allow | 44 | 2 | 1 | No | No |
| 17687373 | ORALLY DISINTEGRATING, SUBLINGUAL AND BUCCAL FORMULATIONS | March 2022 | December 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17674042 | METHOD OF PREPARING AN ANIMAL TREAT COMPOSITION | February 2022 | September 2024 | Allow | 31 | 1 | 0 | Yes | No |
| 17673063 | METHODS FOR MAKING MULTILAYERED VESICLES | February 2022 | September 2025 | Allow | 43 | 3 | 0 | No | No |
| 17665372 | DEVICE FOR CUTTING AN ANIMAL TREAT COMPOSITION | February 2022 | September 2024 | Allow | 32 | 1 | 0 | No | No |
| 17665392 | Systems and Methods for Troche Production | February 2022 | May 2025 | Allow | 39 | 2 | 1 | No | No |
| 17576687 | METHODS OF TREATMENT USING SUSTAINED RELEASE SOTALOL FORMULATIONS | January 2022 | July 2025 | Abandon | 42 | 2 | 0 | No | No |
| 17569047 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS | January 2022 | October 2024 | Allow | 33 | 1 | 0 | No | No |
| 17564812 | SCINTILLATOR NANOCRYSTAL-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | December 2021 | August 2024 | Allow | 31 | 1 | 0 | Yes | No |
| 17530096 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | November 2021 | March 2024 | Allow | 28 | 2 | 0 | Yes | Yes |
| 17528543 | BIO-ADHESIVE DISSOLVING COMPOUNDS AND DEVICE | November 2021 | July 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17452996 | LIQUID LOADING COMPOSITION, METHOD OF MAKING AND USE THEREOF | October 2021 | August 2024 | Allow | 33 | 1 | 0 | No | No |
| 17502701 | Stable Therapeutic Formulations | October 2021 | February 2026 | Abandon | 52 | 3 | 1 | No | No |
| 17497381 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | October 2021 | December 2022 | Allow | 14 | 2 | 0 | Yes | No |
| 17497393 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | October 2021 | December 2022 | Allow | 14 | 2 | 0 | Yes | No |
| 17497366 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | October 2021 | September 2022 | Allow | 11 | 2 | 1 | Yes | No |
| 17494180 | NITRIC OXIDE TOPICAL APPLICATION APPARATUS AND METHODS | October 2021 | November 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17485447 | CANNABIS CALIBRATION SYSTEM-DERIVED PRODUCTS AND METHOD OF MAKING SAME | September 2021 | February 2026 | Abandon | 52 | 1 | 0 | No | No |
| 17485446 | METHOD FOR INCREASING THC/CBD CONTENT IN A CANNABIS PRODUCT | September 2021 | February 2026 | Abandon | 52 | 1 | 1 | No | No |
| 17442239 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | September 2021 | June 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17478117 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | September 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17475528 | SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO AN EYE COMPARTMENT | September 2021 | August 2024 | Allow | 35 | 2 | 1 | No | No |
| 17467655 | Taxane Particles and Their Use | September 2021 | February 2025 | Abandon | 41 | 2 | 0 | No | No |
| 17460476 | METHOD FOR TREATMENT OF DEPRESSION WITH ORAL DOSAGE FORMS OF KETAMINE | August 2021 | March 2025 | Allow | 42 | 3 | 0 | Yes | No |
| 17398413 | ANTI-ODOR COMPOSITIONS, STRUCTURES HAVING ANTI-ODOR CHARACTERISTICS, METHODS OF MAKING THE ANTI-ODOR COMPOSITIONS AND THE STRUCTURES | August 2021 | May 2025 | Allow | 45 | 4 | 0 | Yes | No |
| 17353149 | ORALLY DISINTEGRATING, SUBLINGUAL AND BUCCAL FORMULATIONS | June 2021 | February 2022 | Allow | 8 | 1 | 0 | Yes | No |
| 17304309 | METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUG | June 2021 | December 2023 | Allow | 30 | 1 | 0 | No | No |
| 17347469 | Solid Oral Sulfate Salt Formulations For Cleansing A Colon And Methods Of Using Same | June 2021 | February 2022 | Allow | 8 | 1 | 0 | No | No |
| 17340973 | Solid Oral Sulfate Salt Formulations For Cleaning A Colon And Methods of Using Same | June 2021 | August 2022 | Allow | 14 | 2 | 0 | No | No |
| 17335235 | Submucosal Lifting Compositions and Methods of Same | June 2021 | March 2024 | Allow | 33 | 4 | 1 | Yes | No |
| 17298408 | ADHESIVE PAD | May 2021 | July 2025 | Allow | 49 | 3 | 0 | Yes | No |
| 17328633 | MICROFLUIDIC EXTRUSION | May 2021 | February 2022 | Allow | 8 | 1 | 0 | No | No |
| 17328854 | Microfluidic Extrusion | May 2021 | March 2022 | Allow | 10 | 3 | 0 | Yes | No |
| 17314272 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISEASES IN HUMAN SUBJECTS | May 2021 | December 2024 | Allow | 43 | 2 | 0 | No | No |
| 17291073 | MEDICAMENTS CONTAINING RIBOFLAVIN EXHIBITING IMPROVED FLOWABILITY | May 2021 | January 2024 | Allow | 32 | 1 | 0 | Yes | No |
| 17244158 | NITRIC OXIDE TOPICAL APPLICATION APPARATUS AND METHODS | April 2021 | January 2024 | Allow | 33 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SASAN, ARADHANA.
With a 38.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SASAN, ARADHANA works in Art Unit 1615 and has examined 1,140 patent applications in our dataset. With an allowance rate of 61.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner SASAN, ARADHANA's allowance rate of 61.8% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SASAN, ARADHANA receive 2.17 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SASAN, ARADHANA is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +23.3% benefit to allowance rate for applications examined by SASAN, ARADHANA. This interview benefit is in the 69% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 26.1% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 42.9% of cases where such amendments are filed. This entry rate is in the 66% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 73.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 60% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 79.2% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 63.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 44.9% are granted (fully or in part). This grant rate is in the 38% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 3.2% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.7% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.